home / stock / tkphf / tkphf news


TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 12/18/23

Stock Information

Company Name: Takeda Pharmaceutical Co Ltd
Stock Symbol: TKPHF
Market: OTC
Website: takeda.com

Menu

TKPHF TKPHF Quote TKPHF Short TKPHF News TKPHF Articles TKPHF Message Board
Get TKPHF Alerts

News, Short Squeeze, Breakout and More Instantly...

TKPHF - Wave Life Sciences: What To Make Of The Discounted Offering

2023-12-18 11:24:00 ET Summary Wave Life Sciences Ltd. raised $100 million in a discounted public offering, causing a decline in their stock price. The market reaction may have been incorrect, as the company has positive proof of concept data and major partnerships with Takeda and...

TKPHF - MoonLake Immunotherapeutics: Poised For Acquisition

2023-12-07 23:57:14 ET Summary MoonLake Therapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. Their lead product candidate, Sonelokimab, has shown best-in-class potential in treating Hidradenitis suppurativa and P...

TKPHF - Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For

2023-11-28 12:33:17 ET Summary Ascendis Pharma A/S reported strong sequential growth of Skytrofa and raised its full-year net sales guidance range. The NDA resubmission for TransCon PTH is expected by mid-November, with FDA feedback by mid-December and a potential PDUFA date in Ja...

TKPHF - ImmunoGen: Elahere Data Mid-2024 To Expand Targeted Population

2023-11-27 17:41:15 ET Summary ImmunoGen, Inc. expects to convert the Accelerated Approval of its drug Elahere to "Full Approval" in the 1st half of 2024. Potential European approval of Elahere for treatment of patients with FRa-high platinum-resistant ovarian cancer expected late...

TKPHF - Analyzing The Acquisition Potential Of ImmunoGen

2023-10-31 15:25:10 ET Summary ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck, may be interested in ImmunoGen. ImmunoGen has...

TKPHF - Amicus Therapeutics: The Right Play Now

2023-10-31 12:24:58 ET Summary Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Opfolda for Pompe disease. Amicus Therapeutics i...

TKPHF - Ironwood Pharmaceuticals: The Right Play Now

2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...

TKPHF - Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript

2023-10-27 02:02:10 ET Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Pl...

TKPHF - Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations

2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...

TKPHF - Following Up On Phathom Pharmaceuticals

2023-10-05 12:43:14 ET Summary Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter w...

Previous 10 Next 10